PerkinElmer, Inc. (NYSE:PKI) Director Alexis P. Michas sold 5,000 shares of PerkinElmer stock in a transaction dated Thursday, November 30th. The stock was sold at an average price of $73.18, for a total value of $365,900.00. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
Shares of PerkinElmer, Inc. (NYSE:PKI) traded down $0.56 on Friday, hitting $73.12. The stock had a trading volume of 467,175 shares, compared to its average volume of 631,420. The company has a debt-to-equity ratio of 0.44, a quick ratio of 2.09 and a current ratio of 2.59. PerkinElmer, Inc. has a 12-month low of $50.51 and a 12-month high of $74.11. The company has a market cap of $8,060.00, a PE ratio of 26.55, a P/E/G ratio of 2.21 and a beta of 0.77.
The business also recently declared a quarterly dividend, which will be paid on Friday, February 9th. Stockholders of record on Friday, January 19th will be given a $0.07 dividend. The ex-dividend date of this dividend is Thursday, January 18th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.38%. PerkinElmer’s dividend payout ratio is currently 12.67%.
A number of hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its position in PerkinElmer by 2.6% in the 2nd quarter. Vanguard Group Inc. now owns 10,886,642 shares of the medical research company’s stock valued at $741,816,000 after acquiring an additional 273,975 shares in the last quarter. Janus Henderson Group PLC bought a new position in PerkinElmer in the 2nd quarter valued at approximately $436,483,000. BlackRock Inc. lifted its position in PerkinElmer by 2.4% in the 2nd quarter. BlackRock Inc. now owns 5,929,277 shares of the medical research company’s stock valued at $404,022,000 after acquiring an additional 141,650 shares in the last quarter. Pictet Asset Management Ltd. lifted its position in PerkinElmer by 2.1% in the 2nd quarter. Pictet Asset Management Ltd. now owns 3,433,659 shares of the medical research company’s stock valued at $216,526,000 after acquiring an additional 71,540 shares in the last quarter. Finally, King Luther Capital Management Corp lifted its position in PerkinElmer by 1.3% in the 3rd quarter. King Luther Capital Management Corp now owns 2,562,833 shares of the medical research company’s stock valued at $176,759,000 after acquiring an additional 32,248 shares in the last quarter. 91.66% of the stock is currently owned by institutional investors and hedge funds.
PerkinElmer Company Profile
PerkinElmer, Inc is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets.
Receive News & Ratings for PerkinElmer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.